GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Baudax Bio Inc (OTCPK:BXRXQ) » Definitions » Beneish M-Score

Baudax Bio (Baudax Bio) Beneish M-Score : 6.28 (As of May. 21, 2024)


View and export this data going back to 2019. Start your Free Trial

What is Baudax Bio Beneish M-Score?

The zones of discrimination for M-Score is as such:

An M-Score of equal or less than -1.78 suggests that the company is unlikely to be a manipulator.
An M-Score of greater than -1.78 signals that the company is likely to be a manipulator.

Warning Sign:

Beneish M-Score 6.28 higher than -1.78, which implies that the company might have manipulated its financial results.

The historical rank and industry rank for Baudax Bio's Beneish M-Score or its related term are showing as below:

BXRXQ' s Beneish M-Score Range Over the Past 10 Years
Min: -10.24   Med: -0.54   Max: 6.28
Current: 6.28

During the past 6 years, the highest Beneish M-Score of Baudax Bio was 6.28. The lowest was -10.24. And the median was -0.54.


Baudax Bio Beneish M-Score Historical Data

The historical data trend for Baudax Bio's Beneish M-Score can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Baudax Bio Beneish M-Score Chart

Baudax Bio Annual Data
Trend Dec17 Dec18 Dec19 Dec20 Dec21 Dec22
Beneish M-Score
Get a 7-Day Free Trial - - - 2.51 -8.45

Baudax Bio Quarterly Data
Dec18 Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23
Beneish M-Score Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -10.24 -8.45 2.43 -1.17 6.28

Competitive Comparison of Baudax Bio's Beneish M-Score

For the Biotechnology subindustry, Baudax Bio's Beneish M-Score, along with its competitors' market caps and Beneish M-Score data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Baudax Bio's Beneish M-Score Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Baudax Bio's Beneish M-Score distribution charts can be found below:

* The bar in red indicates where Baudax Bio's Beneish M-Score falls into.



Baudax Bio Beneish M-Score Calculation

The M-score was created by Professor Messod Beneish. Instead of measuring the bankruptcy risk (Altman Z-Score) or business trend (Piotroski F-Score), M-score can be used to detect the risk of earnings manipulation. This is the original research paper on M-score.

The M-Score Variables:

The M-score of Baudax Bio for today is based on a combination of the following eight different indices:

M=-4.84+0.92 * DSRI+0.528 * GMI+0.404 * AQI+0.892 * SGI+0.115 * DEPI
=-4.84+0.92 * 0+0.528 * 1.0143+0.404 * 2.1594+0.892 * 3.1725+0.115 * 1.4417
-0.172 * SGAI+4.679 * TATA-0.327 * LVGI
-0.172 * 0.2462+4.679 * 1.500073-0.327 * 0.7828
=6.28

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

This Year (Sep23) TTM:Last Year (Sep22) TTM:
Total Receivables was $0.00 Mil.
Revenue was 0 + 0 + 0 + 1.269 = $1.27 Mil.
Gross Profit was 0 + 0 + 0 + -4.482 = $-4.48 Mil.
Total Current Assets was $1.34 Mil.
Total Assets was $20.58 Mil.
Property, Plant and Equipment(Net PPE) was $6.55 Mil.
Depreciation, Depletion and Amortization(DDA) was $2.26 Mil.
Selling, General, & Admin. Expense(SGA) was $19.00 Mil.
Total Current Liabilities was $19.05 Mil.
Long-Term Debt & Capital Lease Obligation was $2.53 Mil.
Net Income was -1.934 + -7.375 + 11.404 + -9.249 = $-7.15 Mil.
Non Operating Income was 3.649 + -3.268 + -2.698 + -21.407 = $-23.72 Mil.
Cash Flow from Operations was -2.413 + -3.446 + -4.664 + -3.783 = $-14.31 Mil.
Total Receivables was $0.31 Mil.
Revenue was 0 + 0 + 0 + 0.4 = $0.40 Mil.
Gross Profit was -0.97 + -0.061 + -0.226 + -0.176 = $-1.43 Mil.
Total Current Assets was $11.27 Mil.
Total Assets was $17.51 Mil.
Property, Plant and Equipment(Net PPE) was $1.24 Mil.
Depreciation, Depletion and Amortization(DDA) was $0.73 Mil.
Selling, General, & Admin. Expense(SGA) was $24.33 Mil.
Total Current Liabilities was $21.28 Mil.
Long-Term Debt & Capital Lease Obligation was $2.18 Mil.




1. DSRI = Days Sales in Receivables Index

Measured as the ratio of Revenue in Total Receivables in year t to year t-1.

A large increase in DSR could be indicative of revenue inflation.

DSRI=(Receivables_t / Revenue_t) / (Receivables_t-1 / Revenue_t-1)
=(0 / 1.269) / (0.313 / 0.4)
=0 / 0.7825
=0

2. GMI = Gross Margin Index

Measured as the ratio of gross margin in year t-1 to gross margin in year t.

Gross margin has deteriorated when this index is above 1. A firm with poorer prospects is more likely to manipulate earnings.

GMI=GrossMargin_t-1 / GrossMargin_t
=(GrossProfit_t-1 / Revenue_t-1) / (GrossProfit_t / Revenue_t)
=(-1.433 / 0.4) / (-4.482 / 1.269)
=-3.5825 / -3.531915
=1.0143

3. AQI = Asset Quality Index

AQI is the ratio of asset quality in year t to year t-1.

Asset quality is measured as the ratio of non-current assets other than Property, Plant and Equipment to Total Assets.

AQI=(1 - (CurrentAssets_t + PPE_t) / TotalAssets_t) / (1 - (CurrentAssets_t-1 + PPE_t-1) / TotalAssets_t-1)
=(1 - (1.338 + 6.548) / 20.583) / (1 - (11.269 + 1.239) / 17.51)
=0.616868 / 0.285665
=2.1594

4. SGI = Sales Growth Index

Ratio of Revenue in year t to sales in year t-1.

Sales growth is not itself a measure of manipulation. However, growth companies are likely to find themselves under pressure to manipulate in order to keep up appearances.

SGI=Sales_t / Sales_t-1
=Revenue_t / Revenue_t-1
=1.269 / 0.4
=3.1725

5. DEPI = Depreciation Index

Measured as the ratio of the rate of Depreciation, Depletion and Amortization in year t-1 to the corresponding rate in year t.

DEPI greater than 1 indicates that assets are being depreciated at a slower rate. This suggests that the firm might be revising useful asset life assumptions upwards, or adopting a new method that is income friendly.

DEPI=(Depreciation_t-1 / (Depreciaton_t-1 + PPE_t-1)) / (Depreciation_t / (Depreciaton_t + PPE_t))
=(0.727 / (0.727 + 1.239)) / (2.259 / (2.259 + 6.548))
=0.369786 / 0.256501
=1.4417

Note: If the Depreciation, Depletion and Amortization data is not available, we assume that the depreciation rate is constant and set the Depreciation Index to 1.

6. SGAI = Sales, General and Administrative expenses Index

The ratio of Selling, General, & Admin. Expense(SGA) to Sales in year t relative to year t-1.

SGA expenses index > 1 means that the company is becoming less efficient in generate sales.

SGAI=(SGA_t / Sales_t) / (SGA_t-1 /Sales_t-1)
=(18.998 / 1.269) / (24.325 / 0.4)
=14.970843 / 60.8125
=0.2462

7. LVGI = Leverage Index

The ratio of total debt to Total Assets in year t relative to yeat t-1.

An LVGI > 1 indicates an increase in leverage

LVGI=((LTD_t + CurrentLiabilities_t) / TotalAssets_t) / ((LTD_t-1 + CurrentLiabilities_t-1) / TotalAssets_t-1)
=((2.528 + 19.051) / 20.583) / ((2.175 + 21.275) / 17.51)
=1.048389 / 1.339235
=0.7828

8. TATA = Total Accruals to Total Assets

Total accruals calculated as the change in working capital accounts other than cash less depreciation.

TATA=(IncomefromContinuingOperations_t - CashFlowsfromOperations_t) / TotalAssets_t
=(NetIncome_t - NonOperatingIncome_t - CashFlowsfromOperations_t) / TotalAssets_t
=(-7.154 - -23.724 - -14.306) / 20.583
=1.500073

An M-Score of equal or less than -1.78 suggests that the company is unlikely to be a manipulator. An M-Score of greater than -1.78 signals that the company is likely to be a manipulator.

Baudax Bio has a M-score of 6.28 signals that the company is likely to be a manipulator.


Baudax Bio Beneish M-Score Related Terms

Thank you for viewing the detailed overview of Baudax Bio's Beneish M-Score provided by GuruFocus.com. Please click on the following links to see related term pages.


Baudax Bio (Baudax Bio) Business Description

Traded in Other Exchanges
N/A
Address
490 Lapp Road, Malvern, PA, USA, 19355
Baudax Bio Inc is a Pharmaceutical company. The company develops and commercialize products for hospital and related acute care settings. Its products are in pipeline which includes two novel neuromuscular blocking agents, or NMBAs.
Executives
Natalie Mcandrew officer: Interim CFO C/O BAUDAX BIO, INC., 490 LAPP ROAD, MALVERN PA 19355
Yong Chan Kim director C/O BAUDAX BIO, INC., 490 LAPP ROAD, MALVERN PA 19355
Winston J Churchill director C/O SCP PARTNERS, SUITE 300, 1200 LIBERTY RIDGE DRIVE, WAYNE PA 19087
William Ashton director C/O HARRISON CONSULTING GROUP, PO BOX 283, NEWTOWN SQUARE PA 19073
Andrew T Drechsler director 10 FINDERNE AVENUE, BUILDING 10, BRIDGEWATER NJ 08807
Arnold M Baskies director 1235 SEQUOIA ROAD, CHERRY HILL NJ 08003
Wayne Weisman director 490 LAPP ROAD, MALVERN PA 19355
Jillian Dilmore officer: Corporate Controller/Secretary, other: PFO and PAO C/O BAUDAX BIO, INC., 490 LAPP ROAD, MALVERN PA 19355
Geraldine Henwood director, officer: President and CEO 88 SIDNEY ST, CAMBRIDGE MA 02139
Richard S Casten officer: Chief Financial Officer 490 LAPP ROAD, MALVERN PA 19355
Alfred Altomari director C/O AGILE THERAPEUTICS, INC., 101 POOR FARM ROAD, PRINCETON NJ 08540
Ryan David Lake director, officer: Chief Financial Officer KENSEY NASH CORPORATION, 735 PENNSYLVANIA DRIVE, EXTON PA 19341
Recro Pharma, Inc. 10 percent owner 1 E. UWCHLAN AVE, SUITE 112, EXTON PA 19341